(RxWiki News) The US Food and Drug Administration (FDA) has approved a new medication to treat chronic obstructive pulmonary disease (COPD).
That medication is Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol. It is approved to treat COPD, which includes chronic bronchitis and/or emphysema.
COPD, associated with air pollution, cigarette smoking and occupational exposure, is estimated to affect 329 million people worldwide, according to AstraZeneca, which manufactures the new drug. COPD is considered a progressive disease and causes breathing trouble.
Bevespi Aerosphere is a single product containing two medications. Together, these medications may make breathing easier because they work to relax the muscles around the airways in your lungs.
Clinical trial data suggested that Bevespi Aerosphere improves lung function.
This medication is available as an inhaler and is typically used twice a day. It uses Co-Suspension Technology, which ensures a consistent dose of both medications.
Common side effects seen in clinical trials included urinary tract infection and cough.
